{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:50:04Z","timestamp":1772643004226,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s13730-018-0306-5","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T09:34:09Z","timestamp":1516181649000},"page":"110-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Capillary leak syndrome as a complication of antibody-mediated rejection treatment: a case report"],"prefix":"10.1007","volume":"7","author":[{"given":"Juan C.","family":"Ramirez-Sandoval","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Varela-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E.","family":"Morales-Buenrostro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"306_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/j.1600-6143.2009.02612.x","volume":"9","author":"MD Stegall","year":"2009","unstructured":"Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant. 2009;9:998\u20131005.","journal-title":"Am J Transplant"},{"key":"306_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/nep.12459","volume":"20","author":"Y-H Sin","year":"2015","unstructured":"Sin Y-H, Kim Y-J, Oh JS, Lee JH, Kim SM, Kim JK. Treatment of acute antibody-mediated rejection using bortezomib: a case report. Nephrology. 2015;20:86\u20139.","journal-title":"Nephrology"},{"key":"306_CR3","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/nep.12157","volume":"18","author":"M-G Kim","year":"2013","unstructured":"Kim M-G, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, et al. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology. 2013;18:820\u20136.","journal-title":"Nephrology"},{"key":"306_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.7326\/0003-4819-153-2-201007200-00005","volume":"153","author":"KM Druey","year":"2010","unstructured":"Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 2010;153:90\u20138.","journal-title":"Ann Intern Med"},{"key":"306_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens L, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"306_CR6","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","volume":"86","author":"MJ Everly","year":"2008","unstructured":"Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86:1754\u201361.","journal-title":"Transplantation"},{"key":"306_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/TP.0b013e318257acf6","volume":"94","author":"N Schmidt","year":"2012","unstructured":"Schmidt N, Alloway RR, Walsh RC, Sadaka B, Shields AR, Girnita AL, et al. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation. 2012;94:352\u201361.","journal-title":"Transplantation"},{"key":"306_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1345\/aph.1M585","volume":"44","author":"SC Hsiao","year":"2010","unstructured":"Hsiao SC, Wang MC, Chang H, Pei SN. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma. Ann Pharmacother. 2010;44:587\u20139.","journal-title":"Ann Pharmacother"},{"key":"306_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"306_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00277-010-1022-1","volume":"90","author":"WY Shi","year":"2011","unstructured":"Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, et al. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia\/lymphoma. Ann Hematol. 2011;90:53\u20138.","journal-title":"Ann Hematol"},{"key":"306_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1745-6215-15-107","volume":"15","author":"F Eskandary","year":"2014","unstructured":"Eskandary F, Bond G, Schwaiger E, Kikic Z, Winzer C, Wahrmann M, et al. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT study): study protocol for a randomized controlled trial. Trials. 2014;15:107.","journal-title":"Trials"},{"key":"306_CR12","unstructured":"Leyva S, Marino L, Alber\u00fa J, Morales-Buenrostro LE. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n in Mexico City: an update. Clin Transpl. 2010;35:369\u201382."},{"key":"306_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3346\/jkms.2014.29.5.648","volume":"29","author":"KS Yang","year":"2014","unstructured":"Yang KS, Jeon H, Park Y, Jo IH, Kim J-I, Moon IS, et al. Use of bortezomib as anti-humoral therapy in kidney transplantation. J Korean Med Sci. 2014;29:648\u201351.","journal-title":"J Korean Med Sci"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-018-0306-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-018-0306-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-018-0306-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T19:57:25Z","timestamp":1547668645000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-018-0306-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1007\/s13730-018-0306-5","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]},"assertion":[{"value":"28 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number SALUD-2006-C01-45085 for project: \u201cEvaluaci\u00f3n de la seguridad y eficacia del bortezomib en pacientes receptores de trasplante renal con rechazo agudo mediado por anticuerpos\u201d) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}